Prescient Therapeutics Limited (ASX:PTX) disclosed that it has signed two global licenses for development of chimeric immune receptor platform ‘OmniCAR’-
- An exclusive global licensing agreement with the Trustees of the University of Pennsylvania for an innovative universal immune receptor technology platform.
- Other global, non-exclusive licence from Oxford University to utilize the SpyTag/SpyCatcher molecular binding system employed by the platform.
Notably, Prescient intends to incorporate the technologies from both universities and other assets possessed by PTX for building a universal chimeric immune receptor platform for next-generation cell therapy product development called OmniCAR.
The new platform would facilitate in-house development of next-generation engineered cell therapies and build opportunities for business development and collaboration in the cell therapy arena for Prescient.
Post announcement PTX shares climbed by 13.333% to AUD 0.051 on 26 May 2020 (at 11:22 AM).
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.